Baird Assumes Danaher (DHR) at Outperform
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Baird analyst Catherine Schulte assumes coverage on Danaher (NYSE: DHR) with a Outperform rating and a price target of $249.00.
The analyst comments "We view DHR as a high-quality, core holding recommendation within the life science tools space, with attractive end-market exposures, high recurring revenue mix, and a strong capital deployment track record. We view the 2021 setup for DHR favorably, with overlapping COVID testing and vaccine/therapeutic tailwinds boosting what should be improving underlying end markets. Longer term, we think growth drivers like bioprocessing and point-of-care diagnostics could drive ~6% sustainable organic growth, with solid margin expansion and the potential for incremental M&A."
Shares of Danaher closed at $227.05 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Stephens Starts First Solar (FSLR) at Overweight
- Lindt & Spruengli (LISN:SW) (LDSVF) PT Raised to CHF106,000 at UBS
- UPDATE: Stephens Starts Enphase Energy (ENPH) at Overweight, 'Leading Microinverter Company'
Create E-mail Alert Related CategoriesAnalyst Comments, New Coverage
Related EntitiesRobert W Baird
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!